Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neracorvir (GST-HG141) in chronic hepatitis B with inadequate antiviral response
NCT07090759Phase 3Recruiting
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of narecovir in Chronic Hepatitis B (CHB), sponsored by Fujian Akeylink Biotechnology Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07090759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090759.